Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety

Abstract

Read online

Keywords

• advocacy program
• centralised regulatory procedure
• hybrid application
• nanomedicines
• nanosimilars
• follow-on products